Physician
Testimonial:
"Cesium-131 brachy-therapy is nothing less than a new standard of care for treatment of prostate cancer, giving patients an improved quality of life and peace of mind," says Dr. Dattatreyudu Nori, Professor of Clinical Radiology at Weill Medical College of Cornell University and Radiation Oncologist-in-Chief at New York-Presbyterian/Weill Cornell.
A pioneer in the field of brachytherapy, Dr. Nori was among those who helped introduce Iodine-125 in 1970 and Palladium-103 in 1985. "The introduction of a new isotope has happened every 15 to 20 years," he says.
Cesium-131 brachytherapy is available to low-risk/early-stage prostate cancer patients. In the near future it may also be available to intermediate-risk patients, eliminating the need for supplemental external beam radiation in this population.
For the full text of this article, click here.
|
|
 |
| |
Physicians - Clinicians Information
Introducing the latest technological advancement in prostate cancer seed brachytherapy
 Cesium-131 combines the best physical characteristics of other currently used radioisotopes, a higher energy level than Iodine-125 and a shorter half-life than Palladium-103. The potential clinical benefits of treating your prostate brachytherapy patients with a high energy, short half-life isotope are many and Cesium-131 has the advantage of a higher initial dose rate while using significantly less total dose (115 Gy vs 145 Gy) than I-125. These isotope characteristics translate to a biological life of approximately one month for Cesium-131 versus two months for Palladium-103, and eight months for Iodine-125. The rapid delivery of radiation translates to a lower prescribed dose to create the same biologic effect; specifically, 115 Gy for Cesium-131, 125 Gy for Palladium-103 and 145 Gy for Iodine-125.
Isotope Dose Delivery¹
To read articles and studies on Cesium-131 and related brachytherapy topics, click here. For more information, please contact IsoRay Medical.
|
|
|
|
 |
| |
|
|
| |
Ask your doctor why Cesium-131 could be a better isotope for your prostate cancer therapy. Or request a Cesium-131 brochure, including must know information about prostate cancer, in the mail today. |
|
| |
|
|
| |
|
|
|
| |
|
|
| |
Physician Testimonial:
Steven Kurtzman, M.D.
Director Of Brachytherapy
Western Radiation Oncology
"Cs-131 is potentially the ideal isotope for use in prostate brachytherapy. Its energy of 30.4KeV makes it easy to achieve extremely homogeneous dose distributions while its short half-life delivers the dose quickly. I have performed 30 implants using Cs-131 over the past 6 months and have noted that my patient’s acute side effects are resolving in roughly 4 weeks. The acute side effect profile has been no worse than I-125 or Pd-103. In fact, my early experience suggests that these patients are having somewhat less severe urinary obstructive symptoms acutely. Ongoing clinical trials examining the acute side effect profile of Cs-131 will be completed soon. Overall, I have been extremely pleased with Cs-131 forward to the emergence of data on the tolerability and efficacy of Cs-131 as we go forward." |
|
| |
|
|
| |
|
|
|
